Abstract
Objective
To identify the number of cumulative medication exposures and most frequently used medications in infants with severe BPD.
Study design
We performed a retrospective cohort study in infants with severe BPD admitted to United States children’s hospitals. We measured cumulative medication exposures in individual subjects and between-center variation after adjustment for infant characteristics. We then identified the specific medications and therapeutic classes with the highest rates of use.
Results
In 3252 subjects across 43 hospitals, we identified a median (interquartile range) of 30 (17–45) cumulative medication exposures per infant. The adjusted mean number of medication exposures varied between centers (p < 0.0001), with a range of 22–50. Diuretics and furosemide were the most frequently prescribed therapeutic class and specific medication for the management of severe BPD.
Conclusions
Infants with severe BPD are exposed to alarming number of medications of unclear efficacy and safety, with marked variation between center.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics. 2012;129:1019–26.
Patel RM, Kandefer S, Walsh MC, Bell EF, Carlo WA, Laptook AR, et al. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med. 2015;372:331–40.
Schmidt B, Asztalos EV, Roberts RS, Robertson CMT, Sauve RS, Whitfield MF, et al. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. J Am Med Assoc. 2003;289:1124–9.
Gough A, Spence D, Linden M, Halliday HL, McGarvey LPA. General and respiratory health outcomes in adult survivors of bronchopulmonary dysplasia: a systematic review. Chest. 2012;141:1554–67.
Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723–9.
Lagatta JM, Hysinger EB, Zaniletti I, Wymore EM, Vyas-Read S, Yallapragada S, et al. The impact of pulmonary hypertension in preterm infants with severe bronchopulmonary dysplasia through 1 year. J Pediatr. 2018;203:218–24.
Murthy K, Savani RC, Lagatta JM, Zaniletti I, Wadhawan R, Truog W, et al. Predicting death or tracheostomy placement in infants with severe bronchopulmonary dysplasia. J Perinatol. 2014;34:543–8.
Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116:1353–60.
Government Publishing Office. Public Law 107–109—Jan 4, 2002. Best pharmaceuticals for children act. https://www.govinfo.gov/content/pkg/PLAW-107publ109/pdf/PLAW-107publ109.pdf.
Government Publishing Office. Public Law 108–155—Dec 3, 2003. Pediatric research equity act of 2003. https://www.govinfo.gov/content/pkg/PLAW-108publ155/pdf/PLAW-108publ155.pdf.
Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE, et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr. 2017;181:12–28.
Donn SM. Bronchopulmonary dysplasia: myths of pharmacologic management. Semin Fetal Neonatal Med. 2017;22:354–8.
Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23.
Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK, Smith PB, et al. Medication use in the neonatal intensive care unit. Am J Perinatol. 2014;31:811–21.
Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med. 2012;166:9–16.
Dai D, Feinstein JA, Morrison W, Zuppa AF, Feudtner C. Epidemiology of polypharmacy and potential drug-drug interactions among pediatric patients in ICUs of U.S. children’s hospitals. Pediatr Crit Care Med. 2016;17:e218–28.
Slaughter JL, Stenger MR, Reagan PB. Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. Pediatrics. 2013;131:716–23.
Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Inhaled bronchodilator use for infants with bronchopulmonary dysplasia. J Perinatol. 2015;35:61–6.
Goodman DC. Unwarranted variation in pediatric medical care. Pediatr Clin N Am. 2009;56:745–55.
Brown ER, Stark A, Sosenko I, Lawson EE, Avery ME. Bronchopulmonary dysplasia: possible relationship to pulmonary edema. J Pediatr. 1978;92:982–84.
Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276:357–68.
Abman SH, Rosenberg AA, Lum GM. Management of hyponatremia in infants with bronchopulmonary dysplasia. J Pediatr. 1988;113:789–90.
Perlman JM, Moore V, Siegel MJ, Dawson J. Is chloride depletion an important contributing cause of death in infants with bronchopulmonary dysplasia? Pediatrics. 1986;77:212–6.
Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr. 2012;88:137–42.
Montague EC, Hilinski JA, Williams HO, McCracken CE, Giannopoulos HT, Piazza AJ. Respiratory decompensation and immunization of preterm infants. Pediatrics. 2016;137:e20154225.
Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;9:CD001453.
Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;9:CD001817.
ClinicalTrials.gov. Safety of furosemide in premature infants at risk of bronchopulmonary dysplasia (BPD). https://clinicaltrials.gov/ct2/show/NCT02527798.
Guaman MC, Gien J, Baker CD, Zhang H, Austin ED, Collaco JM. Point prevalence, clinical characteristics, and treatment variation for infants with severe bronchopulmonary dysplasia. Am J Perinatol. 2015;32:960–7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no financial interests to disclose. This work was supported by the National Institutes of Health Institutional National Research Service Award 2T32HD060550-06 to NAB and National Heart, Lung, and Blood Institute Award K23HL136843 to EAJ. The funding sources had no role in the study design; the collection, analysis and interpretation of the data; the writing of the report or the decision to submit for publication. NAB wrote the first draft of the manuscript. No compensation honorarium, grant, or other form of payment was given to produce the manuscript.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bamat, N.A., Kirpalani, H., Feudtner, C. et al. Medication use in infants with severe bronchopulmonary dysplasia admitted to United States children’s hospitals. J Perinatol 39, 1291–1299 (2019). https://doi.org/10.1038/s41372-019-0415-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-019-0415-9
This article is cited by
-
Interdisciplinary clinical bronchopulmonary dysplasia programs: development, evolution, and maturation
Journal of Perinatology (2024)
-
A review and guide to nutritional care of the infant with established bronchopulmonary dysplasia
Journal of Perinatology (2023)
-
Association between postmenstrual age and furosemide dosing practices in very preterm infants
Journal of Perinatology (2022)
-
Qualitative indications for tracheostomy and chronic mechanical ventilation in patients with severe bronchopulmonary dysplasia
Journal of Perinatology (2021)
-
The association between diuretic class exposures and enteral electrolyte use in infants developing grade 2 or 3 bronchopulmonary dysplasia in United States children’s hospitals
Journal of Perinatology (2021)